Hardman Johnston Global Advisors LLC Sells 12,045 Shares of Becton, Dickinson and Company $BDX

Hardman Johnston Global Advisors LLC lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 15.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 66,072 shares of the medical instruments supplier’s stock after selling 12,045 shares during the quarter. Hardman Johnston Global Advisors LLC’s holdings in Becton, Dickinson and Company were worth $12,367,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. SOA Wealth Advisors LLC. boosted its position in Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 95 shares in the last quarter. Bell Investment Advisors Inc boosted its holdings in shares of Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 128 shares in the last quarter. Bank of Jackson Hole Trust grew its position in shares of Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 95 shares during the last quarter. CVA Family Office LLC raised its stake in shares of Becton, Dickinson and Company by 79.5% during the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 97 shares in the last quarter. Finally, CoreFirst Bank & Trust purchased a new stake in Becton, Dickinson and Company during the second quarter valued at approximately $38,000. 86.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BDX shares. Jefferies Financial Group upped their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Bank of America boosted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday, January 5th. Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Argus raised their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Finally, Piper Sandler cut their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $207.64.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total transaction of $123,302.87. Following the completion of the transaction, the executive vice president directly owned 13,105 shares in the company, valued at $2,568,973.15. The trade was a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 1,052 shares of company stock valued at $201,235. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $202.78 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The stock has a 50-day moving average of $193.11 and a two-hundred day moving average of $188.36. The stock has a market cap of $57.77 billion, a P/E ratio of 34.78, a P/E/G ratio of 2.24 and a beta of 0.23. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were given a dividend of $1.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is 72.04%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.